RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2.

Interested parties can register and access the live webcast for the conference .

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

Media Contact:



EN
08/10/2024

Underlying

RANIRANI THERAPEUTICS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provid...

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA...

23h / 26m 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics to Participate in Upcoming Investor Conferences SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include: UBS Global Healthcare Conference Location: Terranea Resort, Rancho Palos Verdes, CADate: Thursday, November 14, 2024 at 10:15am PTFormat: Fireside Chat and 1x1 Meetings S...

November 7, 2024 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Suppo...

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist -Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate ...

October 17, 2024 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Re...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre...

October 15, 2024 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual ...

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2. Interested parties ca...

October 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch